Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based in China, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its investigational drug XS-04 for the treatment of hematologic malignancies.
XS-04, an innovative small molecule drug developed in-house, is designed to target hematologic malignancies, with a particular focus on diffuse large B-cell lymphoma (DLBCL). Preliminary preclinical studies have demonstrated that XS-04 significantly inhibits tumor growth across various blood tumor models and exhibits a favorable safety profile. The drug is anticipated to address the issue of drug resistance often encountered with previous BTK covalent inhibitor treatments.- Flcube.com
